NASDAQ:CNTA Centessa Pharmaceuticals Q4 2024 Earnings Results & Report Centessa Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 24, 2025. The company reported EPS of -$0.34 versus the -$0.38 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 24, 2025TimeBefore Market OpensConference Call7:00 AM ET Centessa Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.38Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCentessa Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Centessa Pharmaceuticals Q4 2024 Earnings FAQ Did Centessa Pharmaceuticals beat earnings estimates for Q4 2024? Centessa Pharmaceuticals (NASDAQ:CNTA) reported earnings of -$0.34 per share for Q4 2024, beating the consensus estimate of -$0.38. The report was announced on Monday, March 24, 2025. Centessa Pharmaceuticals Earnings HeadlinesAcquisition of Centessa by Lilly Approved by the High Court of Justice of England and WalesJune 22, 2026 | globenewswire.comActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline DevelopmentJune 1, 2026 | prnewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?May 12, 2026 | prnewswire.comCentessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTAMay 11, 2026 | businesswire.comIs It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?May 4, 2026 | finance.yahoo.comSee More Centessa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email. Email Address About Centessa PharmaceuticalsCentessa Pharmaceuticals (NASDAQ:CNTA) plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain. Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders. Each affiliated research unit is advancing one or more drug candidates through discovery, preclinical studies and clinical trials. By maintaining strategic agility within its autonomous project teams, Centessa seeks to optimize development timelines and increase the probability of regulatory success. The company was formed in 2021 through an investment consortium and completed its initial public offering via a business combination with Narwhal Acquisition Corp. in early 2022. Headquartered in Cambridge, U.K., Centessa maintains a significant presence in the United States, with research and development sites located in key biotech hubs. This transatlantic footprint enables collaboration with leading academic institutions and access to diverse clinical trial networks. Under the leadership of Chief Executive Officer Knut Brundin, Centessa Pharmaceuticals draws on decades of industry experience to guide its strategic vision. The management team is complemented by veteran drug developers, regulatory experts and academic advisors, all committed to advancing novel therapies from laboratory research to patient care. View Centessa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
